Why Is ALVOTECH (ALVO) Stock Up Today?

Why ALVO stock is up today

Alvotech shares surged 9.26% to $5.49 in the latest session driven by a positive development involving the U.S. Food and Drug Administration and a rating upgrade from Barclays. The stock opened with a 7.8% gap up and reached an intraday high of $5.53 shortly after the market opened. The move reflects optimism around the company’s regulatory progress and revised analyst expectations.

What Happened

Barclays upgraded Alvotech to Overweight and doubled its price target to $8, citing the FDA’s acceptance for review of a Biologics License Application for AVT80. This proposed interchangeable biosimilar to Entyvio is a key milestone for the company. The upgrade followed the FDA inspection outcome and was widely reported in the past 36 hours across four separate stories. Additionally, Alvotech presented at the Morgan Stanley 24th Annual Global Healthcare Conference, where company executives discussed strategic priorities. The stock’s rally was also highlighted in a number of market analysis pieces, though the primary catalyst was the Barclays upgrade and the regulatory filing.

What The Data Shows

Alvotech’s fundamentals remain unprofitable, with a trailing twelve-month net margin of -36.3% and a revenue decline of 12.1%. The stock has a beta of 0.22, indicating low volatility relative to the market. The session’s volume of 0.2 million shares was in line with the 3-month average. On the 52-week tape, the stock hit a fresh 52-week high and a fresh 52-week low on the same day, illustrating the stock’s wide price swings. The session opened at $5.41 and traded as low as $5.25 before settling near $5.43.

What To Watch

Alvotech’s next key event is its presentation at the Morgan Stanley conference, which was held on September 15, 2026. Investors should monitor the breadth of coverage and any follow-up analyst commentary in the coming days.